Palleos Healthcare has a distinguished history of advancing medical innovations, leveraging its extensive experience and network to accelerate the development of new therapies. By integrating academic ...
The positive results from the double-blind period of the RISE UP Phase 2 study, which were presented at the 65 th American Society of Hematology (ASH) Annual Meeting & Exposition in December 2023, ...
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...
A coalition of 12 Philadelphia-area health systems have abandoned the use of race adjustments in four clinical tools ...
The University of California, San Diego (UCSD) is actively seeking participants for five ongoing clinical trials focused on ...
Drug development in oncology is historically challenging, exhibiting a very high attrition rate, with low rates of approval for novel treatments when compared to other therapeutic areas. At present, ...
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Medidata Rave Lite, an extension of the company’s gold-standard ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...
SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder ...
Medical Treatments at the Dawn of AI: Why Drug Development Is Still Slow and How to Get Early Access
With the perpetual rise of technology and the proliferation of AI, we are moving faster than ever. New inventions have accelerated nearly every aspect of our lives, including medicine. In 2023, the ...
LVS Advisory discusses an investment they made in Medpace in the third quarter of 2024. Click here to read more about their ...
Regular Abstracts Accepted as Poster Presentations Presentation Title: Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback